ClinicalTrials.gg
RecruitingNCT06953960Updated Oct 27, 2026

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

A Phase 1/2 interventional study of Surzetoclax and Daratumumab in Multiple Myeloma, sponsored by AbbVie. Recruiting at 51 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 27, 20266 sites added5 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Planned enrollment
22nd of 132
325 · median 50
Started
2025
with 3 others
Phase 1/2
10 of 132
5 open now
Primary completion
2030-12
later than 58 of 62 live
Registered
129th of 132
by date

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 22nd largest by planned enrollment, is one of 4 that started in 2025, is one of 10 in phase 1/2, reaches primary completion later than 58 of the 62 other live ones, and was the 129th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed.

Surzetoclax is an investigational drug being developed for the treatment of R/R MM. In Substudy 1 there will be dose escalation and dose expansion phases where participants will receive various doses (escalation) or 1 of 2 doses (expansion) of surzetoclax in combination with daratumumab + dexamethasone, to determine the best dose of surzetoclax. In Substudy 2, there will be a dose escalation phase where participants will receive various doses of surzetoclax alone. In Substudy 3 there will be dose escalation and optimization phases where participants will receive various doses (escalation) or 1 of 2 doses (optimization) of of surzetoclax and etentamig to determine the best dose of surzetoclax and etentamig. Optimization will also include etentamig received alone. Approximately 325 adult participants with R/R MM will be enrolled in the study in approximately 55 sites worldwide.

In Substudy 1 escalation phase, participants will receive oral surzetoclax tablets in combination with subcutaneous (SC) daratumumab injections + oral dexamethasone tablets and in the expansion phase, will receive 1 of 2 doses oral surzetoclax tablets in combination with SC daratumumab injections + oral dexamethasone tablets or daratumumab injections + oral pomalidomide + oral dexamethasone tablets. In Substudy 2, Japanese participants will receive oral surzetoclax tablets. In Substudy 3 escalation phase, participants will receive oral surzetoclax tablets in combination with IV etentamig and in the expansion phase, will receive 1 of 2 doses of both oral surzetoclax tablets in combination with of IV etentamig, or IV etentamig alone. The total study duration is approximately 4.5 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution. The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • ABBV-453
  • Surzetoclax
  • Daratumumab
  • Dexamethasone
  • Pomalidomide
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of multiple myeloma (MM) based on standard international myeloma working group (IMWG) diagnostic criteria.
  • All participants must have per central laboratory with at least 1 of the following assessed within 28 days prior to enrollment:

    • Serum M-protein >= 0.5 g/dL (>= 5g/L); OR
    • Urine M-protein >= 200 mg/24 hours; OR
    • For participants without measurable serum and urine M-protein: Serum free light chain (sFLC) >= 10 mg/dL (100 mg/L), provided sFLC ratio is abnormal.
  • B-cell lymphoma (BCL)-2 inhibitor treatment naïve.
  • t(11;14) positive status and/or BCL2 high status.
  • Must have confirmed diagnosis of (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen, based on the investigator's determination of the international myeloma working group (IMWG) 2016 criteria.

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 4 weeks of study treatment or planned during study participation.
  • Recent infection requiring systemic treatment that was completed \<= 14 days before first dose of study treatment and/or uncontrolled active systemic infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
325 participants (estimated)

Study arms

  • Experimental
    Substudy 1: Dose Escalation Surzetoclax Combination

    Participants will receive various doses of surzetoclax in combination with daratumumab + dexamethasone, to determine the best dose of surzetoclax, as part of the total 4.5 year study duration.

    Drug: Surzetoclax · Drug: Daratumumab · Drug: Dexamethasone

  • Experimental
    Substudy 1: Dose Optimization & Selection ABBV-453 Combination

    Participants will receive 1 of 2 doses of ABBV-453 in combination with daratumumab + dexamethasone, as part of the total 4.5 year study duration.

    Drug: Surzetoclax · Drug: Daratumumab · Drug: Dexamethasone

  • Active comparator
    Substudy 1: Dose Optimization & Selection Control

    Participants will receive daratumumab, dexamethasone, and pomalidomide, as part of the total 4.5 year study duration.

    Drug: Daratumumab · Drug: Dexamethasone · Drug: Pomalidomide

  • Experimental
    Substudy 2: Dose Escalation ABBV-453 Monotherapy

    Japanese participants will receive various doses of ABBV-453 as a monotherapy, to determine the best dose of ABBV-453, as part of the total 4.5 year study duration.

    Drug: Surzetoclax

  • Experimental
    Substudy 3: Dose Escalation Surzetoclax + Etentamig

    Participants will receive various doses of both surzetoclax and etentamig, to determine the best dose of surzetoclax and etentamig, as part of the total 4.5 year study duration.

    Drug: Surzetoclax · Drug: Etentamig

  • Experimental
    Substudy 3: Dose Optimization Etentamig Dose A Combination

    Participants will receive etentamig dose A in combination with surzetoclax, as part of the total 4.5 year study duration.

    Drug: Surzetoclax · Drug: Etentamig

  • Experimental
    Substudy 3: Dose Optimization Etentamig Dose B Combination

    Participants will receive etentamig dose B in combination with surzetoclax, as part of the total 4.5 year study duration.

    Drug: Surzetoclax · Drug: Etentamig

  • Experimental
    Substudy 3: Dose Optimization Etentamig Monotherapy

    Participants will receive etentamig, as part of the total 4.5 year study duration.

    Drug: Surzetoclax · Drug: Etentamig

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicities (DLT)s of ABBV-453

    DLT events are defined as specific clinically significant adverse events or abnormal laboratory values assessed as events regardless of attribution to ABBV-453, except those clearly and incontrovertibly associated with underlying disease or extraneous causes.

    Time frame: Up to Approximately 45 Months

  2. Number of Participants with Adverse Events (AE)s

    An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 4.5 Years

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR) per Investigator review according to International Myeloma Working Group (IMWG) 2016 criteria.

    Time frame: Up to Approximately 4.5 Years

  2. Progression-Free Survival (PFS)

    PFS is defined as time from first study treatment to the earliest documented disease progression according to IMWG 2016 criteria, as determined by the investigator, or death due to any cause, whichever occurs earlier.

    Time frame: Up to Approximately 4.5 Years

  3. Duration of Response (DOR)

    DOR is defined as the time from the date of achieving the first confirmed sCR/CR/VGPR/PR to the date of recurrence, disease progression according to IMWG 2016 criteria, as determined by the investigator, or death of any cause, whichever occurs earlier.

    Time frame: Up to Approximately 4.5 Years

  4. Time-to-Progression (TTP)

    TTP will be defined as the number of days from the date of first dose to the date of earliest disease progression.

    Time frame: Up to Approximately 4.5 Years

  5. Time to Next Treatment

    Time to next treatment will be defined as the number of days from the date of first dose to the date of next treatment.

    Time frame: Up to Approximately 4.5 Years

  6. Minimal Residual Disease (MRD) Negativity

    MRD negativity is defined as having less than 1 myeloma cell that may remain in the bone marrow aspirate per 10\^5 nucleated cells. Rate of MRD negativity will be determined.

    Time frame: Up to Approximately 4.5 Years

  7. Overall Survival (OS)

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: Up to Approximately 4.5 Years

07

Study locations

51 of 51 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2030, 65 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 65 months is close to that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
May 1, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 5 sites removed
Show 6 added (3 United States, 1 Poland, 1 Sweden, 1 United Kingdom)
  • Yale University School of Medicine /ID# 272447 · New Haven, United States
  • University Of North Carolina Health Care - Hillsborough Campus /ID# 272454 · Hillsborough, United States
  • Atrium Health Wake Forest Baptist Medical Center /ID# 271294 · Winston-Salem, United States
  • Uniwersytecki Szpital Kliniczny w Poznaniu - Szamarzewskiego /ID# 276237 · Poznan, Poland
  • Karolinska Universitetssjukhuset - Huddinge /ID# 271674 · Huddinge, Sweden
  • Oxford University Hospital NHS Trust /ID# 276958 · Oxford, United Kingdom
Show 5 removed
  • Smilow Cancer Center At Yale-New Haven /ID# 272447 · New Haven, United States
  • University of North Carolina at Chapel Hill /ID# 272454 · Chapel Hill, United States
  • Wake Forest Baptist Health /ID# 271294 · Winston-Salem, United States
  • Uniwersytecki Szpital Kliniczny W Poznaniu - Przybyszewskiego /ID# 276237 · Poznan, Poland
  • Karolinska University Hospital Solna /ID# 271674 · Solna, Sweden
across 2 updates, Oct 22, 2026 – Oct 27, 2026
Show all 2 updates
  1. Oct 27, 2026
    1 site added
    Show site
    • Oxford University Hospital NHS Trust /ID# 276958 · Oxford, United Kingdom
  2. Oct 22, 2026
    5 sites added, 5 sites removed
    Show 5 added (3 United States, 1 Poland, 1 Sweden)
    • Yale University School of Medicine /ID# 272447 · New Haven, United States
    • University Of North Carolina Health Care - Hillsborough Campus /ID# 272454 · Hillsborough, United States
    • Atrium Health Wake Forest Baptist Medical Center /ID# 271294 · Winston-Salem, United States
    • Uniwersytecki Szpital Kliniczny w Poznaniu - Szamarzewskiego /ID# 276237 · Poznan, Poland
    • Karolinska Universitetssjukhuset - Huddinge /ID# 271674 · Huddinge, Sweden
    Show 5 removed
    • Smilow Cancer Center At Yale-New Haven /ID# 272447 · New Haven, United States
    • University of North Carolina at Chapel Hill /ID# 272454 · Chapel Hill, United States
    • Wake Forest Baptist Health /ID# 271294 · Winston-Salem, United States
    • Uniwersytecki Szpital Kliniczny W Poznaniu - Przybyszewskiego /ID# 276237 · Poznan, Poland
    • Karolinska University Hospital Solna /ID# 271674 · Solna, Sweden
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06953960
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Jul 23, 2025
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Surzetoclax · Daratumumab · Dexamethasone

Start the discussion